Distinctive gene expression pattern in VH3-21 utilizing B-cell chronic lymphocytic leukemia

被引:36
作者
Fält, S
Merup, M
Tobin, G
Thunberg, U
Gahrton, G
Rosenquist, R
Wennborg, A
机构
[1] Karolinska Inst, Novum, Dept Biosci, Ctr Nutr & Toxicol,Unit Environm Med, SE-14157 Huddinge, Sweden
[2] Karolinska Univ Hosp, Karolinska Inst, Dept Hematol, Stockholm, Sweden
[3] Uppsala Univ, Dept Genet & Pathol, Uppsala, Sweden
[4] Uppsala Univ, Dept Oncol Radiol & Clin Immunol, Uppsala, Sweden
关键词
D O I
10.1182/blood-2004-10-4073
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The usage of the immunoglobulin (19) V(H)3-21 gene is associated with poor prognosis in B-cell chronic lymphocytic leukemia (B-CLL) despite V-H gene mutation status. Many V(H)3-21(+) patients also display restricted heavy- and light-chain Ig gene rearrangements, implying a role of antigen selection in disease development. To explore the specific phenotypic/genotypic features among V(H)3-21(+) B-CLLs, we compared gene expression patterns in 15 V(H)3-21(+) and 24 non-V(H)3-21 patients (11 with unmutated and 13 with mutated V-H genes) using Affymetrix microarray analysis (similar to 12 500 genes). A distinct expression profile was identified for V(H)3-21(+) patients in contrast to the Ig-unmutated and -mutated groups. By applying different algorithms, the data enabled an efflicient class discrimination of the V(H)3-21(+) subset based on 27 or 57 genes. A set of genes was sorted out which, using different analytical methods, consistently gave a distinction between V(H)3-21(+) and non-V(H)3-21 samples. Several of these genes are involved in regulation of DNA replication/cell-cycle control, transcription and protein kinase activity, which may render the V(H)3-21(+) cells with a higher proliferative drive. However, no clear evidence of increased B-cell receptor signaling was found in the V(H)3-21(+) group. Altogether, our identification of a specific V(H)3-21 profile may provide insights into the pathogenesis of the V(H)3-21(+) subgroup.
引用
收藏
页码:681 / 689
页数:9
相关论文
共 47 条
[21]  
Li AH, 1999, EUR J HAEMATOL, V63, P211
[22]   Model-based analysis of oligonucleotide arrays: Expression index computation and outlier detection [J].
Li, C ;
Wong, WH .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (01) :31-36
[23]   High frequency of p53 dysfunction and low level of VH mutation in chronic lymphocytic leukemia patients using the VH3-21 gene segment [J].
Lin, K ;
Manocha, S ;
Harris, RJ ;
Matrai, Z ;
Sherrington, PD ;
Pettitt, AR .
BLOOD, 2003, 102 (03) :1145-1146
[24]  
MATUTES E, 1994, LEUKEMIA, V8, P1640
[25]   Regulation of B-cell fate by antigen-receptor signals [J].
Niiro, H ;
Clark, EA .
NATURE REVIEWS IMMUNOLOGY, 2002, 2 (12) :945-956
[26]   Loss of nuclear expression of the p33ING1b inhibitor of growth protein in childhood acute lymphoblastic leukaemia [J].
Nouman, GS ;
Anderson, JJ ;
Wood, KM ;
Lunec, J ;
Hall, AG ;
Reid, MM ;
Angus, B .
JOURNAL OF CLINICAL PATHOLOGY, 2002, 55 (08) :596-601
[27]   Multivariate analysis of prognostic factors in CLL:: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors [J].
Oscier, DG ;
Gardiner, AC ;
Mould, SJ ;
Glide, S ;
Davis, ZA ;
Ibbotson, RE ;
Corcoran, MM ;
Chapman, RM ;
Thomas, PW ;
Copplestone, JA ;
Orchard, JA ;
Hamblin, TJ .
BLOOD, 2002, 100 (04) :1177-1184
[28]   Five SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin (SMARC) genes are dispersed in the human genome [J].
Ring, HZ ;
Vameghi-Meyers, V ;
Wang, WD ;
Crabtree, GR ;
Francke, U .
GENOMICS, 1998, 51 (01) :140-143
[29]  
Rosenquist R, 1999, EUR J HAEMATOL, V62, P123
[30]   Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia [J].
Rosenwald, A ;
Alizadeh, AA ;
Widhopf, G ;
Simon, R ;
Davis, RE ;
Yu, X ;
Yang, LM ;
Pickeral, OK ;
Rassenti, LZ ;
Powell, J ;
Botstein, D ;
Byrd, JC ;
Grever, MR ;
Cheson, BD ;
Chiorazzi, N ;
Wilson, WH ;
Kipps, TJ ;
Brown, PO ;
Staudt, LM .
JOURNAL OF EXPERIMENTAL MEDICINE, 2001, 194 (11) :1639-1647